中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Menu
Volume 40 Issue 11
Nov.  2024
Turn off MathJax
Article Contents
Abstract
References
Article Navigation >  Journal of Clinical Hepatology  > 2024  >  40(11): 2183-2190

Interpretation of REDISCOVER international guidelines on the perioperative care of surgical patients with borderline-resectable and locally advanced pancreatic cancer （2024）

DOI: 10.12449/JCH241110
  • a.

    Department of Hepatobiliary Surgery，The First Affiliated Hospital of Xi’an Jiaotong University，Xi’an 710061，China

  • b.

    Pancreatic Diagnosis and Treatment Center，The First Affiliated Hospital of Xi’an Jiaotong University，Xi’an 710061，China

Research funding:

National Natural Science Foundation of China (82172853)

More Information
  • Corresponding author: HAN Liang， hanliangxjtu@163.com （ORCID： 0000-0002-3268-5214）
  • Received Date: 2024-08-29
  • Accepted Date: 2024-09-25
  • Published Date: 2024-11-25
    Abstract
  • The REDISCOVER international guidelines on the perioperative care of surgical patients with borderline-resectable and locally advanced pancreatic cancer were released in July 2024， and based on the existing clinical challenges， the guidelines provide important recommendations for the diagnosis， staging， and surgical treatment of borderline-resectable and locally advanced pancreatic cancer from an evidence-based perspective. This article gives an interpretation of the guidelines， in order to better guide clinical practice.

     

    • FullText(HTML)
    • References(51)
  • [1]
    SIEGEL RL, MILLER KD, FUCHS HE, et al. Cancer Statistics, 2021[J]. CA Cancer J Clin, 2021, 71( 1): 7- 33. DOI: 10.3322/caac.21654.
    [2]
    SESHACHARYULU P, BAINE MJ, SOUCHEK JJ, et al. Biological determinants of radioresistance and their remediation in pancreatic cancer[J]. Biochim Biophys Acta Rev Cancer, 2017, 1868( 1): 69- 92. DOI: 10.1016/j.bbcan.2017.02.003.
    [3]
    BEAR AS, VONDERHEIDE RH, O’HARA MH. Challenges and opportunities for pancreatic cancer immunotherapy[J]. Cancer Cell, 2020, 38( 6): 788- 802. DOI: 10.1016/j.ccell.2020.08.004.
    [4]
    KATHER JN, HEIJ LR, GRABSCH HI, et al. Pan-cancer image-based detection of clinically actionable genetic alterations[J]. Nat Cancer, 2020, 1( 8): 789- 799. DOI: 10.1038/s43018-020-0087-6.
    [5]
    National Comprehensive Cancer Network. NCCN guidelines for pancreatic adenocarcinoma(Version 2. 2023)[EB/OL].( 2023-10-22). https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf. https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf
    [6]
    BOGGI U, DEL CHIARO M, CROCE C, et al. Prognostic implications of tumor invasion or adhesion to peripancreatic vessels in resected pancreatic cancer[J]. Surgery, 2009, 146( 5): 869- 881. DOI: 10.1016/j.surg.2009.04.029.
    [7]
    ISAJI S, MIZUNO S, WINDSOR JA, et al. International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017[J]. Pancreatology, 2018, 18( 1): 2- 11. DOI: 10.1016/j.pan.2017.11.011.
    [8]
    OBA A, CROCE C, HOSOKAWA P, et al. Prognosis based definition of resectability in pancreatic cancer: A road map to new guidelines[J]. Ann Surg, 2022, 275( 1): 175- 181. DOI: 10.1097/SLA.0000000000003859.
    [9]
    MAGGINO L, MALLEO G, MARCHEGIANI G, et al. Outcomes of primary chemotherapy for borderline resectable and locally advanced pancreatic ductal adenocarcinoma[J]. JAMA Surg, 2019, 154( 10): 932- 942. DOI: 10.1001/jamasurg.2019.2277.
    [10]
    CONROY T, PFEIFFER P, VILGRAIN V, et al. Pancreatic cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up[J]. Ann Oncol, 2023, 34( 11): 987- 1002. DOI: 10.1016/j.annonc.2023.08.009.
    [11]
    LOOS M, MACK CE, XU ATL, et al. Distal pancreatectomy: Extent of resection determines surgical risk categories[J]. Ann Surg, 2024, 279( 3): 479- 485. DOI: 10.1097/SLA.0000000000005935.
    [12]
    LOOS M, AL-SAEEDI M, HINZ U, et al. Categorization of differing types of total pancreatectomy[J]. JAMA Surg, 2022, 157( 2): 120- 128. DOI: 10.1001/jamasurg.2021.5834.
    [13]
    BOGGI U, KAUFFMANN E, NAPOLI N, et al. REDISCOVER international guidelines on the perioperative care of surgical patients with borderline-resectable and locally advanced pancreatic cancer[J]. Ann Surg, 2024, 280( 1): 56- 65. DOI: 10.1097/SLA.0000000000006248.
    [14]
    BOCKHORN M, UZUNOGLU FG, ADHAM M, et al. Borderline resectable pancreatic cancer: A consensus statement by the International Study Group of Pancreatic Surgery(ISGPS)[J]. Surgery, 2014, 155( 6): 977- 988. DOI: 10.1016/j.surg.2014.02.001.
    [15]
    Scottish Intercollegiate Guidelines Network(SIGN). A guideline developer’s handbook[EB/OL].[ 2024-08-29]. https://www.sign.ac.uk/media/2038/sign50_2019.pdf. https://www.sign.ac.uk/media/2038/sign50_2019.pdf
    [16]
    Grading Tutorial[EB/OL].[ 2024-08-29]. https://www.uptodate.com/home/gradingtutorial. https://www.uptodate.com/home/gradingtutorial
    [17]
    BROUWERS MC, KHO ME, BROWMAN GP, et al. AGREE II: Advancing guideline development, reporting and evaluation in health care[J]. J Clin Epidemiol, 2010, 63( 12): 1308- 1311. DOI: 10.1016/j.jclinepi.2010.07.001.
    [18]
    J EJ, LINSTONE HA, TUROFF M. The Delphi method: Techniques and applications[J]. Technometrics, 1976, 18( 3): 363. DOI: 10.2307/1268751.
    [19]
    AJINA R, WEINER LM. T-cell immunity in pancreatic cancer[J]. Pancreas, 2020, 49( 8): 1014- 1023. DOI: 10.1097/MPA.0000000000001621.
    [20]
    NAPOLI N, KAUFFMANN EF, LOMBARDO C, et al. Postoperative results, learning curve, and outcomes of pancreatectomy with arterial resection: A single-center retrospective cohort study on 236 procedures[J]. Int J Surg, 2023, 110( 10): 6111- 6125. DOI: 10.1097/JS9.0000000000000971.
    [21]
    HE JX, LV N, YANG ZY, et al. Comparing upfront surgery with neoadjuvant treatments in patients with resectable, borderline resectable or locally advanced pancreatic cancer: A systematic review and network meta-analysis of randomized clinical trials[J]. Int J Surg, 2024, 110( 6): 3900- 3909. DOI: 10.1097/JS9.0000000000001313.
    [22]
    BOGGI U. Resection for pancreatic cancer with arterial involvement: A paradigm shift away from unresectable to“how to do it”[J]. Surgery, 2021, 169( 5): 1036. DOI: 10.1016/j.surg.2020.10.047.
    [23]
    REAMES BN, BLAIR AB, KRELL RW, et al. Management of locally advanced pancreatic cancer: Results of an international survey of current practice[J]. Ann Surg, 2021, 273( 6): 1173- 1181. DOI: 10.1097/SLA.0000000000003568.
    [24]
    National Comprehensive Cancer Network. NCCN guidelines for pancreatic adenocarcinoma. Version 1.2024[EB/OL].( 2024-02-10). https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf. https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf
    [25]
    SEELEN LWF, DOPPENBERG D, STOOP TF, et al. Minimum and optimal CA19-9 response after two months induction chemotherapy in patients with locally advanced pancreatic cancer: A nationwide multicenter study[J]. Ann Surg, 2024, 279( 5): 832- 841. DOI: 10.1097/SLA.0000000000006021.
    [26]
    REN L, JÄGER C, SCHORN S, et al. Arterial resection for pancreatic cancer: Feasibility and current standing in a high-volume center[J]. Ann Surg Open, 2023, 4( 3): e302. DOI: 10.1097/AS9.0000000000000302.
    [27]
    STOOP TF, MACKAY TM, BRADA LJH, et al. Pancreatectomy with arterial resection for periampullary cancer: Outcomes after planned or unplanned events in a nationwide, multicentre cohort[J]. Br J Surg, 2023, 110( 6): 638- 642. DOI: 10.1093/bjs/znac353.
    [28]
    FROMER MW, HAWTHORNE J, PHILIPS P, et al. An improved staging system for locally advanced pancreatic cancer: A critical need in the multidisciplinary era[J]. Ann Surg Oncol, 2021, 28( 11): 6201- 6210. DOI: 10.1245/s10434-021-10174-z.
    [29]
    BACHELLIER P, ROSSO E, FUCHSHUBER P, et al. Use of a temporary intraoperative mesentericoportal shunt for pancreatic resection for locally advanced pancreatic cancer with portal vein occlusion and portal hypertension[J]. Surgery, 2014, 155( 3): 449- 456. DOI: 10.1016/j.surg.2013.09.003.
    [30]
    BOGGI U, NAPOLI N, KAUFFMANN EF, et al. Pancreatectomy with resection and reconstruction of the superior mesenteric artery[J]. Br J Surg, 2023, 110( 8): 901- 904. DOI: 10.1093/bjs/znac363.
    [31]
    RATNAYAKE B, PENDHARKAR SA, CONNOR S, et al. Patient volume and clinical outcome after pancreatic cancer resection: A contemporary systematic review and meta-analysis[J]. Surgery, 2022, 172( 1): 273- 283. DOI: 10.1016/j.surg.2021.11.029.
    [32]
    KRAUTZ C, NIMPTSCH U, WEBER GF, et al. Effect of hospital volume on in-hospital morbidity and mortality following pancreatic surgery in Germany[J]. Ann Surg, 2018, 267( 3): 411- 417. DOI: 10.1097/SLA.0000000000002248.
    [33]
    VIVIAN E, BROOKS MR, LONGORIA R, et al. Improving the standard of care for all-a practical guide to developing a center of excellence[J]. Healthcare(Basel), 2021, 9( 6): 777. DOI: 10.3390/healthcare9060777.
    [34]
    GERO D, MULLER X, STAIGER RD, et al. How to establish benchmarks for surgical outcomes? A checklist based on an international expert Delphi consensus[J]. Ann Surg, 2022, 275( 1): 115- 120. DOI: 10.1097/SLA.0000000000003931.
    [35]
    FARGES O, BENDERSKY N, TRUANT S, et al. The theory and practice of pancreatic surgery in France[J]. Ann Surg, 2017, 266( 5): 797- 804. DOI: 10.1097/SLA.0000000000002399.
    [36]
    FARNES I, KLEIVE D, VERBEKE CS, et al. Resection rates and intention-to-treat outcomes in borderline and locally advanced pancreatic cancer: Real-world data from a population-based, prospective cohort study(NORPACT-2)[J]. BJS Open, 2023, 7( 6): zrad137. DOI: 10.1093/bjsopen/zrad137.
    [37]
    VONLANTHEN R, LODGE P, BARKUN JS, et al. Toward a consensus on centralization in surgery[J]. Ann Surg, 2018, 268( 5): 712- 724. DOI: 10.1097/SLA.0000000000002965.
    [38]
    NAPOLI N, KAUFFMANN E, CACACE C, et al. Factors predicting survival in patients with locally advanced pancreatic cancer undergoing pancreatectomy with arterial resection[J]. Updates Surg, 2021, 73( 1): 233- 249. DOI: 10.1007/s13304-020-00883-7.
    [39]
    DIENER MK, MIHALJEVIC AL, STROBEL O, et al. Periarterial divestment in pancreatic cancer surgery[J]. Surgery, 2021, 169( 5): 1019- 1025. DOI: 10.1016/j.surg.2020.08.030.
    [40]
    NELSON DW, BLANCHARD TH, CAUSEY MW, et al. Examining the accuracy and clinical usefulness of intraoperative frozen section analysis in the management of pancreatic lesions[J]. Am J Surg, 2013, 205( 5): 613- 617. DOI: 10.1016/j.amjsurg.2013.01.015.
    [41]
    BOGGI U, KAUFFMANN EF, NAPOLI N, et al. REDISCOVER guidelines for borderline-resectable and locally advanced pancreatic cancer: Management algorithm, unanswered questions, and future perspectives[J]. Updates Surg, 2024, 76( 5): 1573- 1591. DOI: 10.1007/s13304-024-01860-0.
    [42]
    HEGER U, SUN HH, HINZ U, et al. Induction chemotherapy in pancreatic cancer: CA 19-9 may predict resectability and survival[J]. HPB(Oxford), 2020, 22( 2): 224- 232. DOI: 10.1016/j.hpb.2019.06.012.
    [43]
    NEWHOOK TE, VREELAND TJ, GRIFFIN JF, et al. Prognosis associated with CA19-9 response dynamics and normalization during neoadjuvant therapy in resected pancreatic adenocarcinoma[J]. Ann Surg, 2023, 277( 3): 484- 490. DOI: 10.1097/SLA.0000000000005184.
    [44]
    TSAI S, GEORGE B, WITTMANN D, et al. Importance of normalization of CA19-9 levels following neoadjuvant therapy in patients with localized pancreatic cancer[J]. Ann Surg, 2020, 271( 4): 740- 747. DOI: 10.1097/SLA.0000000000003049.
    [45]
    van ROESSEL S, van VELDHUISEN E, KLOMPMAKER S, et al. Evaluation of adjuvant chemotherapy in patients with resected pancreatic cancer after neoadjuvant FOLFIRINOX treatment[J]. JAMA Oncol, 2020, 6( 11): 1733- 1740. DOI: 10.1001/jamaoncol.2020.3537.
    [46]
    MA M, NIU TT, HAO Q, et al. Clinical effect analysis of stereotactic radiotherapy combined with concurrent chemoradiotherapy in the treatment of pancreatic cancer[J]. Trauma Crit Care Med, 2022, 10( 5): 380- 381. DOI: 10.16048/j.issn.2095-5561.2022.05.18.

    马明, 牛婷婷, 郝倩, 等. 立体定向放射治疗联合同步放化疗治疗胰腺癌临床效果分析[J]. 创伤与急危重病医学, 2022, 10( 5): 380- 381. DOI: 10.16048/j.issn.2095-5561.2022.05.18.
    [47]
    WANG CY, LIU XH, WANG XH, et al. Effects of chemoradiotherapy and chemotherapy on survival of patients with locally advanced pancreatic cancer: A meta-analysis of randomized controlled trials[J]. Medicine(Baltimore), 2018, 97( 36): e12260. DOI: 10.1097/MD.0000000000012260.
    [48]
    HOMMA Y, ENDO I, MATSUYAMA R, et al. Outcomes of lung metastasis from pancreatic cancer: A nationwide multicenter analysis[J]. J Hepatobiliary Pancreat Sci, 2022, 29( 5): 552- 561. DOI: 10.1002/jhbp.1127.
    [49]
    HASHIMOTO D, SATOI S, FUJII T, et al. Is surgical resection justified for pancreatic ductal adenocarcinoma with distant abdominal organ metastasis? A position paper by experts in pancreatic surgery at the Joint Meeting of the International Association of Pancreatology(IAP)& the Japan Pancreas Society(JPS) 2022 in Kyoto[J]. Pancreatology, 2023, 23( 6): 682- 688. DOI: 10.1016/j.pan.2023.07.005.
    [50]
    GIANNONE F, CAPRETTI G, HILAL M ABU, et al. Resectability of pancreatic cancer is in the eye of the observer: A multicenter, blinded, prospective assessment of interobserver agreement on NCCN resectability status criteria[J]. Ann Surg Open, 2021, 2( 3): e087. DOI: 10.1097/AS9.0000000000000087.
    [51]
    GODHI SA, PARASAR K, SALUJA S, et al. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer[J]. Ann Surg, 2017, 265( 6): E73. DOI: 10.1097/SLA.0000000000001322.
    • Relative Articles

  • Relative Articles

    [1]Xueying LIU, Huihui SHI, Haowen WANG, Tao YANG. The material basis and toxic mechanism of herb-induced liver injury[J]. Journal of Clinical Hepatology, 2024, 40(8): 1512-1518. doi: 10.12449/JCH240802
    [2]Chenghai LIU. Research advances and challenges in herb-induced liver injury[J]. Journal of Clinical Hepatology, 2024, 40(8): 1505-1511. doi: 10.12449/JCH240801
    [3]Yinuo DONG, Yang ZHI, Jieting TANG, Yimin MAO. Diagnosis of herb-induced liver injury： Challenges in practice[J]. Journal of Clinical Hepatology, 2024, 40(8): 1533-1537. doi: 10.12449/JCH240805
    [4]Tingting HE, Zhaofang BAI, Jiabo WANG, Xiaohe XIAO. Phenotypic characteristics and toxicological mechanisms of herb-induced liver injury[J]. Journal of Clinical Hepatology, 2024, 40(8): 1525-1532. doi: 10.12449/JCH240804
    [5]Xin SUN, Qiong LUO, Tao YANG, Chenghai. LIU. Management and treatment of herb-induced liver injury[J]. Journal of Clinical Hepatology, 2024, 40(8): 1538-1542. doi: 10.12449/JCH240806
    [6]Hui ZHENG, Rong SUN. Influence of combined drug administration on herb-induced liver injury[J]. Journal of Clinical Hepatology, 2024, 40(8): 1519-1524. doi: 10.12449/JCH240803
    [7]Zhaofang BAI, Xiaoyan ZHAN, Guiji LYU, Yongping YANG. Blocking and reversing liver fibrosis with traditional Chinese medicine compound prescriptions: Beyond the known frontiers[J]. Journal of Clinical Hepatology, 2023, 39(2): 273-277. doi: 10.3969/j.issn.1001-5256.2023.02.004
    [8]Junhong LIU, Xinyu LI, Miaolei WANG, Boya FU, Linman LI, Hui FANG. Advantages and characteristics of traditional Chinese medicine in the treatment of liver fibrosis[J]. Journal of Clinical Hepatology, 2023, 39(2): 267-272. doi: 10.3969/j.issn.1001-5256.2023.02.003
    [9]Ying FENG, Ke SHI, Xiaohua ZHANG, Li YANG, Xianbo. WANG. Effect of anti-liver fibrosis traditional Chinese medicine therapy on the prognosis of patients with liver cirrhosis and superior mesenteric venous thrombosis[J]. Journal of Clinical Hepatology, 2022, 38(7): 1534-1539. doi: 10.3969/j.issn.1001-5256.2022.07.015
    [10]Luo Qiong, Zhu GeRui, Gu HongTu, Liu Kun, Chen GaoFeng, Xing Feng, Tao YanYan, Liu ChengHai. Liver histopathological features of patients with drug-induced liver injury due to Chinese herbal medicine or Western medicine: A comparative analysis of 50 cases[J]. Journal of Clinical Hepatology, 2020, 36(3): 596-601. doi: 10.3969/j.issn.1001-5256.2020.03.025
    [11]Liu ChengHai, Zhao ZhiMin, Lyu Jing. Advances in the understanding and treatment of liver fibrosis in traditional Chinese medicine[J]. Journal of Clinical Hepatology, 2019, 35(4): 728-733. doi: 10.3969/j.issn.1001-5256.2019.04.006
    [12]Sheng QingShou, Lai GuoQuan, Yu XueJing, Wei Cui. The role of traditional Chinese medicine in regulating cytokines associated with liver fibrosis[J]. Journal of Clinical Hepatology, 2018, 34(12): 2677-2680. doi: 10.3969/j.issn.1001-5256.2018.12.037
    [13]Chen Jun. Drug-induced liver injury caused by Chinese herbal medicine cannot be neglected[J]. Journal of Clinical Hepatology, 2018, 34(6): 1169-1171. doi: 10.3969/j.issn.1001-5256.2018.06.006
    [14]Liu ChengHai, Zhu ChunWu. Epidemic features, major causes, and diagnostic evaluation of herb-induced liver injury[J]. Journal of Clinical Hepatology, 2017, 33(5): 829-832. doi: 10.3969/j.issn.1001-5256.2017.05.007
    [15]Zhu Yun, Wang RuiLin, Sun XueYing, Yu SiMiao, Jing Jing, Wang JiaBo, He TingTing, Huang YiXue, Wang LiPing, Sun YongQiang. Guiding significance of Guideline for diagnosis and treatment of herb-induced liver injury in clinical diagnosis: a retrospective analysis[J]. Journal of Clinical Hepatology, 2016, 32(11): 2159-2162. doi: 10.3969/j.issn.1001-5256.2016.11.032
    [16]Branch of Hepatobiliary Diseases, China Association of Chinese Medicine, Branch of Chinese Patent Medicine, China Association of Chinese Medicine. Guideline for diagnosis and treatment of herb-induced liver injury[J]. Journal of Clinical Hepatology, 2016, 32(5): 835-843. doi: 10.3969/j.issn.1001-5256.2016.05.003
    [17]Li Yang, Xu JianMing. Clinical analysis of 11 cases of hepatic veno-occlusive disease caused by Chinese herbal medicine[J]. Journal of Clinical Hepatology, 2011, 27(2): 140-142.
    [19]Shen FengJun, Yin ChengHong, Ma Hong, Ma XueMei, Jia JiDong, Wang BaoEn, Zhu YueKe, Liu TianHui. Expression of angiotensin Ⅱ type 1 receptors mRNA in rat experimental biliary fibrosis[J]. Journal of Clinical Hepatology, 2002, 18(5): 279-281.
    • Supplements(0)
    • Cited By
  • 加载中
    Created with Highcharts 5.0.7Chart context menuAccess Class DistributionFULLTEXT: 27.3 %FULLTEXT: 27.3 %META: 65.2 %META: 65.2 %PDF: 7.5 %PDF: 7.5 %FULLTEXTMETAPDF
    Created with Highcharts 5.0.7Chart context menuAccess Area Distribution其他: 5.0 %其他: 5.0 %其他: 0.3 %其他: 0.3 %Central District: 0.3 %Central District: 0.3 %China: 0.5 %China: 0.5 %Kao-sung: 0.3 %Kao-sung: 0.3 %Tiruchi: 0.3 %Tiruchi: 0.3 %上海: 5.8 %上海: 5.8 %佛山: 0.3 %佛山: 0.3 %兰州: 0.8 %兰州: 0.8 %北京: 2.3 %北京: 2.3 %南京: 1.5 %南京: 1.5 %南宁: 0.5 %南宁: 0.5 %卡纳塔克: 0.3 %卡纳塔克: 0.3 %合肥: 0.3 %合肥: 0.3 %呼和浩特: 0.3 %呼和浩特: 0.3 %咸阳: 0.3 %咸阳: 0.3 %哥伦布: 0.3 %哥伦布: 0.3 %圣安东尼奥: 0.3 %圣安东尼奥: 0.3 %大连: 0.3 %大连: 0.3 %天津: 0.3 %天津: 0.3 %安阳: 0.3 %安阳: 0.3 %宣城: 0.8 %宣城: 0.8 %山景城: 0.3 %山景城: 0.3 %常州: 0.3 %常州: 0.3 %常德: 0.8 %常德: 0.8 %广州: 0.5 %广州: 0.5 %张家口: 4.8 %张家口: 4.8 %得梅因: 0.3 %得梅因: 0.3 %德阳: 0.3 %德阳: 0.3 %成都: 0.3 %成都: 0.3 %日照: 0.5 %日照: 0.5 %杭州: 0.5 %杭州: 0.5 %武汉: 0.5 %武汉: 0.5 %沈阳: 0.3 %沈阳: 0.3 %泰州: 0.3 %泰州: 0.3 %洛阳: 0.3 %洛阳: 0.3 %海得拉巴: 0.8 %海得拉巴: 0.8 %深圳: 0.5 %深圳: 0.5 %温州: 0.3 %温州: 0.3 %焦作: 0.3 %焦作: 0.3 %眉山: 0.3 %眉山: 0.3 %石家庄: 0.3 %石家庄: 0.3 %科泽科德: 0.3 %科泽科德: 0.3 %红河: 0.5 %红河: 0.5 %芒廷维尤: 29.3 %芒廷维尤: 29.3 %芝加哥: 3.8 %芝加哥: 3.8 %苏州: 0.3 %苏州: 0.3 %莫斯科: 0.5 %莫斯科: 0.5 %衡水: 0.3 %衡水: 0.3 %西宁: 11.0 %西宁: 11.0 %西安: 0.5 %西安: 0.5 %诺沃克: 0.3 %诺沃克: 0.3 %贵阳: 0.5 %贵阳: 0.5 %赣州: 0.3 %赣州: 0.3 %运城: 0.8 %运城: 0.8 %遂宁: 0.5 %遂宁: 0.5 %郑州: 4.5 %郑州: 4.5 %重庆: 1.3 %重庆: 1.3 %金华: 0.3 %金华: 0.3 %长春: 12.8 %长春: 12.8 %长沙: 0.3 %长沙: 0.3 %其他其他Central DistrictChinaKao-sungTiruchi上海佛山兰州北京南京南宁卡纳塔克合肥呼和浩特咸阳哥伦布圣安东尼奥大连天津安阳宣城山景城常州常德广州张家口得梅因德阳成都日照杭州武汉沈阳泰州洛阳海得拉巴深圳温州焦作眉山石家庄科泽科德红河芒廷维尤芝加哥苏州莫斯科衡水西宁西安诺沃克贵阳赣州运城遂宁郑州重庆金华长春长沙

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(2)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (286) PDF downloads(40) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[2713]YesterdayPV[4302]TodayIP[528]TodayPV[865]Online[139]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return